Background-Epicardial vasculopathy has been shown to be associated with poor outcome after heart transplantation. We demonstrate that histologically proven stenotic microvasculopathy is a novel prognostic factor for long-term survival.
T he gradual development of transplant vasculopathy (TVP) is one of the major lethal complications during the long-term course after heart transplantation (HTx). [1] [2] [3] It is characterized by diffuse atherosclerotic alterations of the transplanted heart. 4, 5 Progressive myointimal lesions in epicardial blood vessels 6, 7 and medial thickening [7] [8] [9] in small, intramyocardial coronary arteries finally result in vascular stenosis, leading to acute or chronic graft failure.
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TVP of the large coronary arteries is of proven prognostic impact. [1] [2] [3] 10 Serial screening for epicardial TVP is established in routine follow-up of cardiac transplant recipients, and diagnosis includes the use of international classifications. 11, 12 Diagnosis of small-vessel disease by routinely processed right ventricular biopsies has been described previously. 8, 13, 14 However, published data have not ascertained the prognostic relevance of microvasculopathy for graft survival and therefore do not justify serial screening procedures by right ventricular biopsies. 1, 2 In contrast to these findings in cardiac transplant recipients, nontransplanted patients with microvasculopathy due to diabetes mellitus, amyloidosis, or connective tissue disorders are at increased risk for cardiac-related death. 15, 16 Therefore, we reevaluated the prognostic value of microvasculopathy for survival after HTx in our single-center experience with 9713 right ventricular biopsies taken during the first year after HTx. We propose a biopsyderived graduation system of posttransplantation microvascular alterations, which is easy to apply to routinely processed endomyocardial biopsies and which supports evidence for the prognostic value of biopsy screening of cardiac transplant recipients at predefined time intervals.
Methods
Between April 1986 and December 2002, 1348 patients underwent primary HTx at our hospital. Of these, we excluded pediatric patients (aged Ͻ18 years), patients who died during the first 30 days after transplantation, and those who did not undergo biopsy follow-up within the first posttransplantation year. Eight hundred seventy-three patients were suitable for further analysis. The majority of those patients were male (83%), and the leading indication for HTx was dilated cardiomyopathy (64%). Mean age at HTx was 49.1Ϯ0.6 years, and median survival time, including time to cardiac retransplantation (nϭ16), was 12.4 years (95% CI, 11.4 to 13.5 years).
In these 873 patients, a total of 9713 biopsies were collected (11Ϯ1 biopsies per patient) within the first year after HTx and were investigated in the present study. We chose only biopsies harvested during the first posttransplantation year to clarify whether evidence of stenotic microvasculopathy in early biopsy identifies patients at risk for a serious cardiac event in the later follow-up.
Biopsies were subdivided according to the time intervals in which they were taken, ie, Յ30 days, Ͼ30 to 90 days, Ͼ90 to 180 days, 181 to 270 days, and 271 to 365 days ( Table 1 ). All biopsies harvested from cardiac retransplants were excluded from analyses. All investigations were done retrospectively.
Posttransplantation triple immunosuppression was maintained with cyclosporine A 2 to 4 mg/kg (trough level 250 ng/mL; nϭ829 [95%]) or tacrolimus (trough level 8 to 10 ng/mL; nϭ44 [5%]), mycophenolate 30 to 50 mg/kg (target dose 2 to 3 g/d, white blood cell count not Յ3500/L; nϭ262 [30%]), or azathioprine 1 to 5 mg/kg (white blood cell count not Յ3500/L; nϭ611 [70%]) and prednisolone (target dose 0.15 mg/kg after 2 months). Blood levels of cyclosporine A were measured with the use of an enzyme immune assay. Therapy of acute cellular rejection grades 1A to 2 17 consisted of an oral steroid regimen for 10 days. All rejection of grade 3A 17 or higher or clinically symptomatic rejection was treated with polyclonal antibodies (anti-thymocyte globulin) and steroids for 3 days.
Biopsy Harvest Procedure and Histological Tissue Preparations
The right ventricular biopsies (nϭ9713) were obtained according to standard procedure through a right ventricular approach from the interventricular septum. 18 Histological tissue preparation was performed by hemalum and eosin (H&E) stainings (Mayer's hemalum and eosin, Merck).
Diagnosis of Microvasculopathy
During routine post-cardiac transplantation biopsy procedure, at least 3 tissue sections are harvested and undergo morphological analysis. If we presuppose a section length of 1.0 to 1.5 mm with a cylindrical form, each section provides an area of 1.5 to 2.5 mm 2 . With at least 3 tissue samples, the area is 4.5 to 7.5 mm 2 . If we assume that histological sections are cut at 3 levels, the total area per biopsy is 13.5 to 22.5 mm 2 . In this endomyocardial tissue, arteriolar vascularization accounts for 103Ϯ31 vessels per square millimeter and capillary vascularization for 667Ϯ147 vessels per square millimeter. 9 Diagnosis of microvasculopathy was done by light microscopy (ϫ200). Pathological findings were classified according to the graduation system given in Figure 1 and Table 2 . In microvessels (diameter 10 to 20 m), both the endothelial layer and the wall (medial) layer were identified. The endothelial layer was defined as the monocell layer at the inner part of the blood vessel wall. It was considered normal when there was a thin layer of cells whose diameter was less than the diameter of the endothelial cell cores ( Figure 1A , 1D, and Table 2 ). Endothelial cells were graded as thickened if the diameter of the cell layer was at least as thick as the endothelial cell cores ( Figure 1C and Table 2 ).
The wall layer (media) was defined as the polycell layer adjacent to the endothelium. The adventitia was not characterized separately. The wall was graded as normal if its diameter was less than the luminal radius ( Figure 1A and Table 2 ). Wall thickening was classified as nonstenotic if the ratio of luminal radius to wall thickness was Ͻ3 but Ն1 ( Figure 1B and Table 2 ), and stenotic wall thickening was graded if this ratio was Ͻ1 ( Figure 1C and 1D and Table 2 ). This grading system was generated according to a histomorphometric study of large peripheral arteries described by Hieronymi. 19 Stenotic microvasculopathy was diagnosed if there was evidence of microvascular stenosis due to either endothelial thickening or wall thickening in at least 1 blood vessel per field of view ( Figure 1C and 1D and Table 2 ).
Independent of microvasculopathy, acute cellular rejection was classified according to the International Society for Heart and Lung Transplantation (ISHLT). 17 The investigations were done by 2 pathologists blinded to patient data.
Definition of Epicardial Transplant Vasculopathy
To define the prevalence of epicardial TVP, we evaluated in total 1524 coronary angiographies (9 days to 20.5 years after transplantation) available in 611 patients (70%). Severe epicardial TVP was diagnosed at first presence of Ն75% luminal stenosis. 10
Statistics and Definition of End Points for Kaplan-Meier Analyses
SPSS for Windows version 11.01 was used for statistical analysis. Results are given as number (n) and meanϮSEM (range), if not otherwise indicated.
Analysis of survival and freedom from end points was performed according to Kaplan-Meier estimation. We assigned 2 combined end points: (1) overall survival, which was defined as time to cardiac retransplantation (nϭ16) or death from all causes (nϭ392), ie, coronary artery vasculopathy (including chronic graft failure, acute myocardial infarction, sudden cardiac death), acute cellular rejection, malignancy (including lymphoma), infection (including cytomegalovirus), primary graft failure, multiple organ failure, renal failure, pulmonary causes, cerebrovascular causes, and others 3, 20 ; and (2) time to fatal cardiac event, 21 ie, time to cardiac retransplantation, chronic graft failure, lethal acute myocardial infarction, or sudden cardiac death (nϭ94).
Survival in different patient groups was compared with the log-rank test. In Kaplan-Meier analyses, endothelial thickening and nonstenotic and stenotic microvasculopathy were tested separately as determinant factors. Individuals were allocated to (1) patients with evidence of at least 1 diseased biopsy in the 1-year sample volume and compared with patients without evidence of diseased biopsy in the 1-year sample volume. To explore whether the prognostic impact of biopsy screening within the first posttransplantation year is linked to continuous or time-related biopsy follow-ups, we tested (2) in each time interval patients with evidence of at least 1 diseased biopsy and compared them with patients showing no evidence of diseased biopsy in the same time interval. A Cox proportional hazards model was used to investigate possible risk factors for fatal cardiac event or retransplantation. A univariate approach was followed by a multivariate Cox regression with backward elimination procedure. Odds ratio was calculated for evidence of microvasculopathy beyond the first 3 months after transplantation in the case of detection at Ͼ30 to 90 days after HTx. Univariate and multivariate (backward elimina- 
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tion procedure) logistic regression analysis was performed to identify risk factors for stenotic microvasculopathy. PϽ0.05 was considered statistically significant. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results

Prevalence of Microvasculopathy and Severe Epicardial Vasculopathy
Stenotic microvasculopathy was present in 379 of 873 patients (43%) and was due to concentric medial disease (345/379; 91%) rather than concentric endothelial disease (2/379; 1%) or a combination of both (31/379; 8%; 2 ϭ519.884, PϽ0.001). Once developed, stenotic microvasculopathy correlated significantly with subsequent evidence of stenotic microvasculopathy in biopsy (odds ratio, 2.77; 95% CI, 1.90 to 4.04; PϽ0.001). Severe epicardial TVP was recorded in 118 of 612 patients (19%) at a mean time of 5.7Ϯ0.2 years after transplantation. Single-vessel disease was found in 50 cases (42%), double-vessel disease in 31 cases (26%), and triple-vessel disease in 37 cases (34%).
Freedom From Stenotic Microvasculopathy and Severe Epicardial Vasculopathy
Freedom from microvasculopathy at 3, 6, 9, and 12 months after transplantation was 64Ϯ3%, 44Ϯ3%, 35Ϯ3%, and 
Microvasculopathy and Fatal Cardiac Events
Freedom from serious cardiac event or cardiac retransplantation (nϭ552) at 1, 5, and 10 years after transplantation was 97.6Ϯ0.7%, 92.6Ϯ1.1%, and 83.6Ϯ1.8%, respectively.
When the 1-year biopsy sample volume was analyzed, freedom from fatal cardiac event was not decreased in the presence of endothelial thickening or nonstenotic wall thickening. In addition, the time point of biopsy harvest indicating endothelial thickening or nonstenotic wall thickening was not correlated with decreased freedom from fatal cardiac events.
Stenotic microvasculopathy evidenced by stenotic wall thickening was the only parameter that decreased freedom from fatal cardiac events (Figure 3 ), and this effect was independent of epicardial TVP. Further analyses of time points of biopsy harvest procedures within the first posttransplant year showed that stenotic microvasculopathy evidenced at Ͼ30 to 90 days and Ͼ270 to 365 posttransplant days was associated with high rates of fatal cardiac events, whereas no correlation was found with stenotic microvasculopathy evidenced at Յ30 days, Ͼ90 to 180 days, and Ͼ180 to 270 days ( Figure 4 ).
Cox proportional hazards analyses for fatal cardiac events, ie, cardiac-related death (excluding acute cellular rejection) and cardiac retransplantation, are presented in Table 3 . In univariate regression analyses, we found stenotic microvasculopathy evident in at least 1 biopsy of the 1-year sample volume, in at least 1 biopsy harvested at days Ͼ30 to 90 or at days Ͼ270 to 365, or in at least 1 of both time intervals; nonstenotic microvasculopathy or endothelial thickening evident in at least 1 biopsy of the 1-year sample volume; the number and grade of acute cellular rejection episodes; the pretransplant conditions of recipient cytomegalovirus positive at HTx, donor age, and transplant year before 1992; and the clinical parameters of treated diabetes mellitus and epicardial vasculopathy to be associated with fatal cardiac events, whereas treated arterial hypertension, female recipient gender, and dilated cardiomyopathy before HTx were inversely correlated with fatal cardiac events.
However, in multivariate regression analysis (Table 3) , we found only stenotic microvasculopathy evidenced in at least 1 
Correlation of Stenotic Microvasculopathy in Biopsy and Severe Epicardial Vasculopathy in Angiography
Freedom from epicardial TVP in patients without stenotic microvasculopathy at 1, 3, 5, 7, 10, and 15 years was 100%, 98Ϯ2%, 98Ϯ2%, 96Ϯ3%, 93Ϯ4%, and 80Ϯ7%, respectively, and in patients with microvasculopathy at the same intervals was 99Ϯ1%, 98Ϯ1%, 95Ϯ2%, 94Ϯ2%, 87Ϯ3%, and 81Ϯ4%, respectively (Pϭ0.4510).
Because, except for 1 patient, all cases of stenotic epicardial TVP were diagnosed beyond the first year, we tested the correlation of stenotic microvasculopathy evident within the first posttransplantation year with later evidence of epicardial TVP. Here we found only patients with stenotic microvasculopathy at Ͼ270 to 365 days after transplantation to be at higher risk of later developing stenotic 3-vessel disease in coronary angiography (odds ratio, 3.28 [95% CI, 1.16 to 9.27]; Pϭ0.025) with involvement of the left coronary artery (2.56 [1.24 to 5.30]; Pϭ0.011).
Risk Factors for Stenotic Microvasculopathy
At all time points of biopsy harvest, we found a correlation between endothelial thickening and stenotic microvasculopathy, ie, at days Ͼ30 to 90 (Pearson correlation coefficient rϭ0.220; Pϭ0.001), Ͼ90 to 180 (rϭ0.193; Pϭ0.003), Ͼ180 to 270 (rϭ0.308; PϽ0.0001), and Ͼ270 to 360 (rϭ0.241; PϽ0.0001) after transplantation.
In univariate regression analyses for stenotic microvasculopathy in at least 1 biopsy of the 1-year sample volume (Table 4) , the following were identified as significant risk factors: at least 1 biopsy with nonstenotic microvasculopathy within the first 90 days, at least 1 biopsy with endothelial thickening within the first 270 days, acute cellular rejection of any grade (overall prevalence of ISHLT grades 1A to 2 in 40% [3864/9713] and ISHLT grades 3A to 4 in 9% [864/ 9713] of biopsies), coronary heart disease as diagnosis leading to HTx, and transplant years before 1992. Ischemic and reperfusion times, donor age, assist device before HTx, positive cytomegalovirus status at HTx, at least 1 episode of treated cytomegalovirus infection after transplantation, renal insufficiency (serum creatinine Ͼ1.6 mg/dL), and treated hyperlipidemia were correlated with lower evidence of stenotic microvasculopathy. However, the majority of patients with renal insufficiency (70%; 535/761) were treated additionally for hyperlipidemia (PϽ0.0001).
Multivariate regression analysis ( 
Discussion
In the present study we describe in a representative cohort of 873 HTx patients the prevalence and prognostic impact of early microvasculopathy in routinely processed endomyocardial biopsies. We found that stenotic microvasculopathy after HTx is a medial disease that affects Ͼ40% of cardiac transplant recipients within the first posttransplantation year. It is associated with both poor overall survival and reduced freedom from fatal cardiac events if evident in at least 1 biopsy harvested within the first posttransplantation year, independently of epicardial TVP.
We chose the intimal and medial layers as target parameters for small-vessel disease in biopsy because both endothelial cells and smooth muscle cells play a central role in the development of TVP. 21, 22 In support of data published by ourselves and others, [7] [8] [9] 23 we found stenotic microvasculopathy as a consequence of medial disease but without intimal thickening, which has been identified as a major pathological finding in epicardial TVP. 6, 7 Thus, TVP after HTx presents itself as concentric medial disease in the microvasculature and as intimal disease in epicardial coronary arteries. 6, 7 Our finding that evidence of stenotic microvasculopathy in biopsy as early as within the first postoperative year is relevant for long-term prognosis after HTx has been suggested previously. 13 However, we present longitudinal data from a large cohort of patients and investigated the impact on clinical outcomes, which has not been reported earlier. We proved the prognostic impact of stenotic microvasculopathy in at least 1 biopsy of the total sample volume for the development of fatal cardiac events. According to the multivariate Cox proportional hazards model, we also showed evidence of stenotic microvasculopathy in at least 1 biopsy at posttransplantation days Ͼ30 to 90 and Ͼ270 to 365 together with severe epicardial vasculopathy and diabetes mellitus to be relevant for risk estimation of fatal cardiac events. However, we also identified "intermediate" lesions that were nonstenotic and not associated with poor survival or fatal cardiac events. According to Armstrong and colleagues 23 and our previous observations, 9 these findings might represent microvascular remodeling after HTx, characterized by an increase of vascular smooth muscle ␣-actin over time. Thus, posttransplantation microvascular alterations might not be graded primarily as disease 24 but rather as a transplant-related, "physiological" process. Follow-up data in this field are mandatory and may provide evidence for the impact of this microvascular remodeling on the later development of stenotic microvasculopathy.
Endothelial cell swelling has been characterized before in terms of antibody-mediated rejection. 25 We did not investigate vascular deposition of immunoglobulin and complement because our primary target was to establish morphological criteria for microvascular disease in routinely processed biopsies with impact on survival. We proved that endothelial thickening alone was not correlated with poor survival, but it was significantly associated with evidence of stenotic microvasculopathy. Endothelial cells play a central role in the development of epicardial TVP 21 and have been suggested as "key operators" in the "response to injury model," finally leading to obstructive coronary lesions in the transplanted heart. 26 Although we could not determine the origin of endothelial thickening, we suggest a change in the endothelial cell surface as initiating the development of microvasculopathy. 26 We demonstrated acute cellular rejections of ISHLT grades Յ2 17 as risk factors for the development of stenotic microvasculopathy, which supports our hypothesis that microvasculopathy is an immune-mediated phenomenon, similar to epicardial TVP. 21 Furthermore, this finding supports our own strategy of treating even low-grade acute cellular rejection with increased immunosuppression. Stenotic microvasculopathy in biopsy seems to be a de novo process in the transplanted heart rather than an effect due to imported lesions because we found a correlation with younger donor age. Furthermore, coronary heart disease as a primary cause of HTx was not confirmed as a risk factor in multivariate regression analysis, suggesting only weak effects of classic cardiovascular risk factors in the development of stenotic microvasculopathy, which has also been demonstrated for epicardial TVP. 21 Proliferation of vascular smooth muscle cells has been demonstrated in the development of stenotic microvasculopathy; however, this process was discontinued beyond the first 3 posttransplantation months. 9 Thus, mechanisms other than microvascular stenosis itself may play a role in microvasculopathy at the end of the first posttransplantation year and its effects on serious cardiac events in further follow-up. Because we found a strong correlation between endothelial disease and stenotic microvasculopathy at any time after HTx, we suggest a shift from an early immunogenic to a later prothrombotic endothelium phenotype to be causal for poor prognosis of stenotic microvasculopathy at the end of the first year. Enhanced platelet activation has been described in the development and progression of epicardial vasculopathy 27 and might be involved in our finding of lower risk for microvasculopathy in patients on assist device before transplantation, who are usually on antiplatelet therapy. Clopidogrel is known to have antithrombotic and antagonistic effects on smooth muscle cell proliferation, 28 and we suggest that it may be a novel approach in prevention and treatment of transplant vasculopathy in epicardial and small intramyocardial blood vessels. Our study also supports a known prophylactic approach to transplant vasculopathy, which is the use of statins. 29 We suggest beneficial effects of early statin treatment on the epicardial 29 and microvascular level because we demonstrated patients with treated hyperlipidemia to be at low risk for stenotic microvasculopathy within the first posttransplantation year. Although we found, as for epicardial TVP, an era effect, 3 which might be due to different strategies in the posttransplantation management of comorbidities, we failed to demonstrate as risk factors for microvasculopathy greater age of recipients or donor grafts, female gender, or cytomegalovirus, which have been shown to have an impact on the development of epicardial TVP. 21, 30, 31 This might be due, at least in part, to different etiopathogenetic pathways for intima-related epicardial and media-related microvascular manifestation of this disease. In support of this partial overlap hypothesis, evidence of stenotic microvasculopathy at Ͼ270 to 365 days after transplantation identified patients with higher risk for the development of stenotic epicardial TVP in further follow-up and may be useful as a surrogate marker for subsequent severe epicardial TVP.
We did not analyze the impact of different immunosuppressive regimens on the development of microvasculopathy in biopsy because the number of patients on tacrolimus or mycophenolate was low. Thus far, published treatments focus exclusively on preventive and therapeutic strategies for epicardial vasculopathy 20, 29 ; however, our data demonstrate the need to include stenotic microvasculopathy in biopsy as a novel target lesion in future clinical trials.
Study Limitations
The histomorphometric evaluation of biopsies was performed retrospectively; therefore, we have initiated a prospective clinical trial to confirm our results in a longitudinal observational study protocol. The tissue sections investigated here were restricted to right ventricular endomyocardium, and a sampling bias cannot be excluded. No functional tests were performed to evaluate the hemodynamic significance of microvasculopathy. This was due to the retrospective design of the study and was why we chose overall survival and fatal cardiac events as reliable end points.
Conclusion
Pathological features of the microvascular endothelial and wall layer in routinely processed posttransplantation biopsies are frequent and not necessarily associated with poor outcome. Evidence of stenotic microvasculopathy in biopsy, however, has a prognostic impact on survival after HTx and is associated with fatal cardiac events independently of epicardial vasculopathy. The graduation of microvascular findings proposed here is easy to apply in routinely processed endomyocardial tissue sections. It provides evidence for the prognostic value of time-dependent biopsy screening of cardiac transplant recipients for microvasculopathy, and closer attention should be given to stenotic microvasculopathy evident in biopsies harvested within the first and the last 3 months of the first year after HTx. Patients with stenotic microvasculopathy are at increased risk of developing stenotic epicardial disease and should undergo angiographic follow-up to identify potential epicardial target lesions. Early statin therapy and aggressive treatment of acute cellular rejection within the first posttransplantation year independent of grade may prove to be promising preventive strategies for microvasculopathy and deserve further study.
